Sign in

Bill Ling

Vice President and Senior Equity Research Analyst at Leerink Partners

Bill Ling, Ph.D., is a Vice President and Senior Equity Research Analyst at Leerink Partners specializing in emerging oncology, where he delivers detailed coverage of companies including Adaptimmune Therapeutics, Bicycle Therapeutics, and Genmab. With a background in chemical engineering from Caltech, Ling has been recognized for his in-depth equity research and consistently provides data-driven investment ratings and forecasts, though public third-party performance metrics such as TipRanks rankings or published long-term returns are not currently available. He began his finance career after earning his Ph.D. in 2023, joining Leerink Partners to focus on biopharma equities with a quantitative approach informed by his technical expertise. Ling is FINRA-registered, holding Series 7 and 63 securities licenses, reflecting his strong professional and regulatory credentials.

Bill Ling's questions to Innate Pharma (IPHA) leadership

Question · Q2 2025

Bill Ling asked about the implications of Innate Pharma's strategic shift away from ANKET assets and Eric Vivier's departure on the future of NK cell targeting.

Answer

Jonathan Dickinson, CEO, clarified that Eric Vivier will continue as an R&D advisor and through an extended research collaboration. He stated that while NK cells are not the current main priority, IPH6501 studies are ongoing, and future decisions will be based on clinical data and market relevance, emphasizing it's not the 'end of NK cells.'

Ask follow-up questions

Question · Q2 2025

Bill Ling from Leerink Partners inquired about the implications of Innate Pharma's strategic shift away from ANKET® assets and NK cell targeting, as well as the departure of Chief Scientific Officer Eric Vivier.

Answer

CEO Jonathan Dickinson clarified that Eric Vivier will continue as an advisor to the R&D Committee and through an extended research collaboration. He emphasized that while NK cells are no longer a main priority, IPH6501 studies continue, and future decisions will be based on clinical data and market relevance.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts